Page last updated: 2024-08-17

nad and Kahler Disease

nad has been researched along with Kahler Disease in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19902 (20.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's4 (40.00)24.3611
2020's3 (30.00)2.80

Authors

AuthorsStudies
Elnenaei, MO; Gujar, SA; Kennedy, BE; Reiman, A; Sadek, M1
Ali, SA; Borrello, IM; de Souza Fernandes Pereira, M; Elmas, E; Ghiaur, G; Imus, PH; Lee, DA; Naeimi Kararoudi, M; Nagai, Y; Wethington, D1
Aguennouz, M; Alibrandi, A; Allegra, A; Allegra, AG; Di Giorgio, RM; Innao, V; Musolino, C; Oteri, G; Oteri, R; Polito, F1
Bam, R; Barlogie, B; Epstein, J; Khan, S; Li, X; Ling, W; Usmani, S; van Rhee, F; Venkateshaiah, SU; Yaccoby, S1
Acharya, C; Anderson, KC; Cagnetta, A; Calimeri, T; Cea, M; Chauhan, D; Fulciniti, M; Gobbi, M; Hideshima, T; Munshi, N; Nencioni, A; Patrone, F; Richardson, P; Tai, YT; Zhong, MY1
Beauparlant, P; Bédard, D; Bernier, C; Chan, H; Gilbert, K; Goulet, D; Gratton, MO; Lavoie, M; Roulston, A; Turcotte, E; Watson, M1
Anderson, KC; Cagnetta, A; Calimeri, T; Cea, M; Chauhan, D; Cottini, F; Fulciniti, M; Gobbi, M; Hideshima, T; Jakubikova, J; Kong, SY; Munshi, N; Nencioni, A; Patrone, F; Richardson, P; Roccaro, A; Sacco, A; Tai, YT1
Anderson, KC; Cagnetta, A; Cea, M; Gobbi, M; Nencioni, A; Patrone, F1
AURICCHIO, S; QUAGLIARIELLO, E; RINALDI, E; VIOLANTE, A1
Ehrhart, H; Hörmann, W; Kienle, H1

Other Studies

10 other study(ies) available for nad and Kahler Disease

ArticleYear
Targeting NAD
    Trends in cancer, 2020, Volume: 6, Issue:1

    Topics: Acrylamides; Adenosine; Adenosine Diphosphate Ribose; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytokines; Drug Synergism; Humans; Membrane Glycoproteins; Multiple Myeloma; NAD; Niacinamide; Nicotinamide Phosphoribosyltransferase; Piperidines; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Escape; Warburg Effect, Oncologic

2020
CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.
    Blood, 2020, 11-19, Volume: 136, Issue:21

    Topics: Adoptive Transfer; ADP-ribosyl Cyclase 1; Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; CRISPR-Cas Systems; Cytotoxicity, Immunologic; Humans; Immunotherapy; Killer Cells, Natural; Male; Membrane Glycoproteins; Mice; Mice, Inbred NOD; Multiple Myeloma; NAD; Oxidative Phosphorylation; Specific Pathogen-Free Organisms; Tretinoin; Whole Genome Sequencing

2020
SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma.
    Clinical biochemistry, 2021, Volume: 93

    Topics: Aged; Biomarkers; Bone Diseases; Case-Control Studies; Female; Gene Expression Regulation, Neoplastic; Glutathione Peroxidase; Healthy Volunteers; Humans; Hydrogen Peroxide; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; NAD; Oxidation-Reduction; Oxidative Stress; Sirtuin 2; Sirtuin 3

2021
NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
    Experimental hematology, 2013, Volume: 41, Issue:6

    Topics: Acrylamides; Animals; Bone and Bones; Cell Differentiation; Coculture Techniques; Cytokines; Enzyme Induction; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mice; Mice, SCID; Multiple Myeloma; NAD; Neoplasm Proteins; NF-kappa B; Niacinamide; Nicotinamide Mononucleotide; Nicotinamide Phosphoribosyltransferase; Osteoclasts; Osteolysis; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Rabbits; Sirtuin 1; Tumor Cells, Cultured; Up-Regulation

2013
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
    Blood, 2013, Aug-15, Volume: 122, Issue:7

    Topics: Acrylamides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Case-Control Studies; Caspases; Cell Proliferation; Drug Synergism; Female; Fluorescent Antibody Technique; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; NAD; Neoplasm Recurrence, Local; NF-kappa B; Nicotinamide Phosphoribosyltransferase; Oligonucleotide Array Sequence Analysis; Piperidines; Poly(ADP-ribose) Polymerases; Prognosis; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2013
Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
    Anti-cancer drugs, 2009, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line, Tumor; Colonic Neoplasms; Cyanides; Cytokines; Drug Screening Assays, Antitumor; Female; Guanidines; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Multiple Myeloma; NAD; Neoplasm Proteins; Niacin; Niacinamide; Nicotinamide Phosphoribosyltransferase; Prodrugs; Xenograft Model Antitumor Assays

2009
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
    Blood, 2012, Oct-25, Volume: 120, Issue:17

    Topics: Acrylamides; Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Survival; Cytokines; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Multiple Myeloma; Multiprotein Complexes; NAD; Nicotinamide Phosphoribosyltransferase; Organ Specificity; Piperidines; Proteins; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2012
Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells.
    Autophagy, 2013, Volume: 9, Issue:3

    Topics: Acrylamides; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Lentivirus; Multiple Myeloma; NAD; Piperidines; Transcription, Genetic

2013
On the effect of DPN on the conversion of 3-hydroxyanthranilic acid to quinolinic acid in presence of hepatic tissue of rats affected by Oberling's myeloma in the leukemic phase.
    Clinica chimica acta; international journal of clinical chemistry, 1958, Volume: 3, Issue:5

    Topics: 3-Hydroxyanthranilic Acid; Animals; Coenzymes; Leukemia; Leukemia, Myeloid; Liver; Multiple Myeloma; NAD; Pyridines; Quinolinic Acid; Rats

1958
[Quantitative changes of coenzymes and substrates of Glycolysis in rat-Myeloma following cytostatic therapy with C 73 in various dosage].
    Klinische Wochenschrift, 1970, May-15, Volume: 48, Issue:10

    Topics: Adenine Nucleotides; Adenosine Triphosphate; Alkylating Agents; Animals; Coenzymes; Glycolysis; Multiple Myeloma; NAD; Neoplasms, Experimental; Rats

1970